1.The existence way for hospital library with the aid of library colleague advantages
Chinese Journal of Medical Library and Information Science 2015;(3):62-64
After the difficult position of hospital library and the experiences of Shanghai Public Health Clinical Center Library in meeting clinical and medical needs were described, such as relying on the advantages of Fudan library col-league, improving professional literacy, providing subject service, and expanding service contents, the author pointed out that providing excellent service through multiple channels and ways is the key for hospital library to improve its value and position and its sustainable development .
2.Clinical feature and genetic characteristics in common mitochondrial diseases of children
Chinese Journal of Applied Clinical Pediatrics 2014;29(24):1841-1843
Mitochondrial diseases is one of the common genetic metabolic diseases in children.The inheritance patterns are complex,both mendelian inheritance and mitochondrial maternal inheritance.Although the clinical feature is various and the diagnosis is difficult,but with the development of molecular biology,some clinical and genetic features in mitochondrial syndrome were gradually clear.This paper introduced the clinical feature and genetic characteristics in several common mitochondrial syndrome of children.
3.Researching Progress on Medical Plants of Commelina
International Journal of Traditional Chinese Medicine 2008;30(6):474-476
There are about 170 kinds of medical plants of Commelina all over the world.Experimental studies showed that the main chemical compositions in the plants included alkaloids,flavonoids,terpenes,and sterols etc.Plants of commelina,especially commelina communis,have pharmacological activities of antibacterial,antiinflammation,resisting-oxidation,lowering-glycemia,relieving-pain and stopping-cough etc.It is necessary that their pharmacological effects and chemical compositions are further developed and investigated systematically.
4.Immune abnormalities in autism.
Chinese Journal of Pediatrics 2015;53(8):636-639
5.Design, synthesis and biological evaluation of the novel trehalose derivatives.
Acta Pharmaceutica Sinica 2015;50(6):725-732
Using brartemicin as the leading compound, fifteen novel trehalose derivatives were designed and synthesized, and the structures were determined by 11H NMR, MS and element analysis. Inhibitory effects of the target compounds on the proliferation of A549, HepG2 and HUVEC cells were detectec by MTT assay. The abilities of adhesion, invasion and migration of A549 and HepG2 cells inhibited by the synthesized compounds were evaluated through Matrigel experiment and Transwell assay. The results showed that, the target compounds had no significant cytotoxicity (compared with the control, P>0.05) to A549, HepG2 and HUVEC cells at the dose range of 1-32 µmol.L-1. At the above dose range, the inhibitory effects of A549 cells adhesion, invasion and migration and HepG2 cells adhesion and invasion by compounds 79 and 82 are better than brartemicin.
Antineoplastic Agents
;
chemical synthesis
;
pharmacology
;
Cell Adhesion
;
Cell Line, Tumor
;
drug effects
;
Drug Design
;
Hep G2 Cells
;
drug effects
;
Human Umbilical Vein Endothelial Cells
;
drug effects
;
Humans
;
Trehalose
;
analogs & derivatives
;
chemistry
6.Design, synthesis and biological evaluation of the novel trehalose derivatives.
Acta Pharmaceutica Sinica 2015;50(6):725-32
Using brartemicin as the leading compound, fifteen novel trehalose derivatives were designed and synthesized, and the structures were determined by 11H NMR, MS and element analysis. Inhibitory effects of the target compounds on the proliferation of A549, HepG2 and HUVEC cells were detectec by MTT assay. The abilities of adhesion, invasion and migration of A549 and HepG2 cells inhibited by the synthesized compounds were evaluated through Matrigel experiment and Transwell assay. The results showed that, the target compounds had no significant cytotoxicity (compared with the control, P>0.05) to A549, HepG2 and HUVEC cells at the dose range of 1-32 µmol.L-1. At the above dose range, the inhibitory effects of A549 cells adhesion, invasion and migration and HepG2 cells adhesion and invasion by compounds 79 and 82 are better than brartemicin.
7.Current Situation on Sleep Disorders in Menopausal Women
World Science and Technology-Modernization of Traditional Chinese Medicine 2013;(8):1741-1746
Sleep disorders are main clinical symptoms in perimenopausal women. The symptoms are difficulty in initiating or maintaining sleep, early morning awakening and so on. These sleep problems had made serious im-pacts on the quality of women's life during menopausal periods. Menopausal sleep disorders can be caused by changes of serum estrogen levels, vasomotor symptoms, mood disorders and patient's state of disease. This paper presented an overview of inducing factors and current situation of menopausal disorder treatment.
8.Serum Levels and Clinical Significance of Interferon-λ1 in Systemic Lupus Erythematosus Patients
Journal of China Medical University 2010;(2):153-155
Objective To investigate the clinical significance of serum interferon-λ1(IFN-λ1) levels in patients with systemic lupus erythematosus(SLE).Methods ELBA was used to evaluate the serum level of interferon-λ1 in 60 patients with SLE and 20 healthy individuals as normal control.SPSS10.0 statistic software was employed to investigate the relation between the serum IFN-λ1 level,the laboratory index and SLE disease activity index(SLEDAI).Results The serum IFN-λ1 level in SLE patients(74.2±16.1 pg/ml) was higher than that of the normal controls(70.4±12.6 pg/ml,P=0.339).The serum IFN-λ1 level in SLE patients with leucopenia(80.1±18.1 pg/ml) was higher than those of the normal control(P=0.052) and the SLE patients without leucopenia(70.6±13.7 pg/ml,P=0.024).The serum IFN-λ1 level was not correlated with SLEDAI,complements C3,C4,24-hour-proteinuria.Conclusion IFN-λ1 may be involved in the pathogenesis of leukopenia in SLE and it has not been proved that its level was correlated with the disease activity.
9.Clinical observation of the treatment of ischemic heart failure with combination therapy esmolol and labetalol
Chinese Journal of Primary Medicine and Pharmacy 2016;23(9):1329-1332
Objective To study the effect of intravenous injection of esmolol,labetalol and their combination in the treatment of ischemic heart failure (ICD).Methods 80 patients with ICD were randomly divided into treat-ment group 1 (20 cases),treatment group 2(20 cases),treatment group 3 (20 cases)and control group(20 cases). The treatment group 1 was intravenously given esmolol on the basis of routine treatment.the treatment group 2 was intravenously given labetalol on the basis of the conventional treatment.the treatment group 3 was intravenously given esmolol and labetalol on the basis of routine treatment.The control group only received routine treatment.The thera-peutic effects of the four groups were observed and compared,and the changes of blood pressure,heart rate,walking distance and ultrasonic electrocardiogram before and after treatment were recorded.Results In the treatment group 1,3 cases with marked effect,effective in 14 cases,the total effective rate was 85%.In the treatment group 2,2 cases with marked effect,effective in 14 cases,the total effective rate was 80% cases.In the treatment group 3,4 cases with marked effect,effective in 15 cases,the total effective rate was 95%.In the control group,1 case with marked effect, effective in 10 cases,the total effective rate was 55%.The treatment effect of the treatment group 1,2,3 was better than the control group (P <0.05).The treatment effect of the treatment group 1,2 was significantly lower than the treatment group 3 (P <0.05).The treatment effect between the treatment group 1 and group 2 had no significant difference (P >0.05 ).After treatment,6 min walking distance and LVEF,FS,SV and other indicators of cardiac function were significantly improved in the four groups (P <0.05 ).The four groups had no significant adverse reactions such as nausea,vomiting,liver and renal function after treatment.Conclusion Intravenous injection of esmolol,labetalol or both drugs for treatment of ICD can improve cardiac function,with no adverse reaction,and it is safe and reliable,worthy of clinical application.
10.Construction of retrovirus expression vector containing GLUT-2 gene and its identification
Journal of Third Military Medical University 2003;0(11):-
Objective To establish the retrovirus expression vector containing glucose transporter-2 ( GLUT-2) gene and its stable virus producing cell line,for the construction of new "artificial islet beta cells". Methods Plasmid pCB7 /GLUT2 was digested by EcoRⅠ/BamHⅠ and cloned to retroviral vector PLXSN for the construction of recombinant plasmid pL-GLUT2-SN,which was identified by enzyme digestion and sequencing,and then transfected to packaging cell line PA317. Titer of the recombinant virus was detected. Cell lines with a high titer were cloned and identified by PCR and RT-PCR. Results The retrovirus expression vector pL-GLUT2-SN was established,in which the insertion site and reading frame of target gene were confirmed by enzyme digestion and sequence analysis. The highest titer of virus producing cell line PA317 /GLUT2 was 7. 1 ? 105 CFU/mL. PCR and RT-PCR showed that the GLUT-2 gene was integrated into PA317 /GLUT2 and stably expressed. Conclusion A retrovirus expression vector containing GLUT-2 gene and its stable virus producing cell line PA317 /GLUT2 are successfully constructed,thus laying a foundation for the construction of "artificial islet beta cells".